{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI could not be estimated due to insufficient events.","groupId":"OG000","lowerLimit":"5.7","upperLimit":"NA","value":"7.9"},{"comment":"Upper limit of 95% CI could not be estimated due to insufficient events.","groupId":"OG001","lowerLimit":"1.0","upperLimit":"NA","value":"1.0"},{"groupId":"OG002","lowerLimit":"1.0","upperLimit":"2.7","value":"1.2"},{"comment":"Upper limit of 95% CI could not be estimated due to insufficient events.","groupId":"OG003","lowerLimit":"1.2","upperLimit":"NA","value":"1.6"},{"comment":"Upper limit of 95% CI could not be estimated due to insufficient events.","groupId":"OG004","lowerLimit":"2.4","upperLimit":"NA","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"TTP: time from date of first dose to date of first documentation of PD as defined by standard disease criteria. PD was defined as increase of \\>25% from lowest response value in any one or more of following: a) Serum M-component and/or (the absolute increase must be \\>0.5 grams per deciliter \\[g/dL\\]). b) Urine M-component and/or (the absolute increase must be \\>200 mg/24 h). c) Only in participants without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be \\>10 milligrams per deciliter (mg/dL). d) Bone marrow plasma cell percentage; the absolute percentage must be \\>10%. e) Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. f) Development of hypercalcaemia (corrected serum calcium \\>11.5 mg/dL or 2.65 millimoles per liter \\[mmol/L\\]) that can be attributed solely to the plasma cell proliferative disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received TAK-981 60 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG000","title":"Phase 1b, Part 1: TAK-981 60 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG001","title":"Phase 1b, Part 1: TAK-981 90 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG002","title":"Phase 1b, Part 1: TAK-981 90 mg QW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG003","title":"Phase 1b, Part 1: TAK-981 120 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG004","title":"Phase 1b, Part 1: TAK-981 120 mg QW + Mezagitamab 600 mg"}],"paramType":"MEDIAN","populationDescription":"Safety analysis set included participants who received at least 1 dose, even if incomplete, of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug to the date of the first documentation of PD or death, whichever occurred first (up to 12 months)","title":"Phases 1b, Part 1: Time to Progression (TTP) Based on IMWG Criteria","type":"SECONDARY","unitOfMeasure":"months"}